Skip to main content

Table 2 Adverse drug reactions in the safety analysis set

From: Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study

Adverse drug reactions

n

%

Patients evaluated

659

−

Patients with ADRs

42

6.4

ADRs in ≥ 0.3% of patients

  

 Blood CPK increased

10

1.5

 Myalgia

5

0.8

 Gallstone

4

0.6

 Blood creatinine increased

4

0.6

 AST increased

3

0.5

 Gastric cancer

2

0.3

 Diabetes

2

0.3

 Renal dysfunction

2

0.3

 ALT increased

2

0.3

 Blood TG increased

2

0.3

  1. ADRs: adverse drug reactions; CPK: creatine phosphokinase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; TG: triglyceride.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840